Myosin light-chain kinase also known as MYLK or MLCK is a serine/threonine-specific protein kinase that phosphorylates a specific myosin light chain, namely, the regulatory light chain of myosin II.
|CSN22980||MLCK inhibitor peptide 18||224579-74-2||MLCK Inhibitor Peptide 18 is a selective competitive inhibitor of myosin light chain kinase with IC50 of 50 nM.|
|CSN12294||ML-7 hydrochloride||110448-33-4||ML-7 HCl is a multiple-target inhibitor of MLCK with Ki value of 300 nM, PKA with 21μM, and PKC of 42 μM.|
|CSN23710||ML-9||105637-50-1||ML 9 a is myosin light chain kinase (MLCK) inhibitor. ML-9 enhances the anticancer activity of docetaxel, suggesting its potential application as an adjuvant to existing anticancer chemotherapy. The complex effect of ML-9 on autophagy and indentified ML-9 as an attractive tool for targeting autophagy in cancer therapy through dual inhibition of both the Akt pathway and the autophagy.|
|CSN26207||HA-100||84468-24-6||HA-100 is an inhibitor of cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase (IC50 values are 4, 8, 12 and 240 μM, respectively).|
|CSN10984||Fasudil Hydrochloride||105628-07-7||Fasudil HCl is a potent inhibitor of ROCK-II, PKA, PKG, PKC, and MLCK with Ki of 0.33 μM, 1.6 μM, 1.6 μM, 3.3 μM and 36 μM, respectively.|
|CSN33153||W-7 hydrochloride||61714-27-0||Calmodulin antagonist. Inhibits myosin light chain kinase|